Us TOO Advocacy Alert  
April 29, 2011

From: Thomas Kirk, President and CEO

Subject: Give CMS Your Comments on Provenge Access by Friday, April 29

Give CMS Your Comments on Provenge Access by Friday, April 29

Over the last 7 months, nearly 4,000 of you signed the petition to the Centers for Medicare and Medicaid Services (CMS) in support of Medicare access to FDA-approved prostate cancer treatments such as Provenge, a new immunotherapy treatment for advanced prostate cancer. Many of you made additional comments on the CMS website and/or attended the MEDCAC meeting on November 17, 2010 in Baltimore, MD.

Now, CMS is completing their National Coverage Analysis (NCA) for Provenge. They have issued a proposed decision memo stating Provenge is reasonable and necessary for patients who have asymptomatic or minimally systematic castrate-resistant disease and are on Medicare.

Help reinforce the petitioners and add your voice NOW in support of the proposed final determination for national coverage of Provenge as stated by CMS. If you have not already done so, I encourage you to submit your comments here before tomorrow, Friday, April 29, 2011.

Read my comment here

Read the CMS announcement: CMS Initiates Comment Period for Final Determination on Provenge Coverage

Read the original petition here

Thanks to all of you for your attention and timely action. This issue has generated the largest outpouring of voices from the Us TOO network EVER on ANY topic. Together, our voices have made a difference in support of FDA approval and CMS coverage of a new treatment option for men with advanced prostate cancer!

Please forward this email to others who you feel would support and take action today.
Tips for communicating with elected officials | Find your U.S. Senators | Find your U.S. Representatives | Return to Us TOO Advocacy Program page

Facebook -  Twitter -  LinkedIn - Inspire prostate cancer discussions 

Contact Us | Privacy Policy | Terms & Conditions | Disclaimer   

Copyright 2005-2014 Us TOO International, Inc.
Designed and hosted by ACCESS Medical Group, Ltd.